Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Nonsyndromic Hypertrophic Cardiomyopathy Overview

In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
[updated ].
Affiliations
Free Books & Documents
Review

Nonsyndromic Hypertrophic Cardiomyopathy Overview

Allison L Cirino et al.
Free Books & Documents

Excerpt

The purpose of this overview is to:

  1. 1

    Define the clinical characteristics of hypertrophic cardiomyopathy (HCM);

  2. 2

    Review the genetic causes of nonsyndromic HCM;

  3. 3

    Review the differential diagnosis of nonsyndromic HCM;

  4. 4

    Provide an evaluation strategy to identify (when possible) the genetic cause of nonsyndromic HCM in a proband;

  5. 5

    Review the management of HCM;

  6. 6

    Inform genetic counseling of family members of an individual with nonsyndromic HCM.

PubMed Disclaimer

Similar articles

References

    1. Ahluwalia M, Liu J, Olivotto I, Parikh V, Ashley EA, Michels M, Ingles J, Lampert R, Stendahl JC, Colan SD, Abrams D, Pereira AC, Rossano JW, Ryan TD, Owens AT, Ware JS, Saberi S, Helms AS, Day S, Claggett B, Ho CY, Lakdawala NK. The clinical trajectory of NYHA functional class I patients with obstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2025;13:332-43. - PubMed
    1. Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, Shen J, McLaughlin HM, Clark EH, Babb LJ, Cox SW, DePalma SR, Ho CY, Seidman JG, Seidman CE, Rehm HL. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015; 17:880-8. - PubMed
    1. Almomani R, Verhagen JMA, Herkert JC, Brosens E, van Spaedonck-Zwarts KY, Asimaki A, van der Zwaag PA. Frohn-Mulder IME, Bertollo-Avella AM, Boven LG, van Slegtenhorst MA, van der Smagt JJ, van IJcken WFJ, Timmer B, van Stuijvenberg M, Verdijk RM, Saffitz JE, du Plessis FA, Michels M, Hofstra RM, Sinke RJ, van Tintelen JP, Wessels MW, Jongbloed JD, van de Laar IM. Biallelic truncating mutations in ALPK3 cause severe pediatric cardiomyopathy. J Am Coll Cardiol. 2016; 67: 515-25. - PubMed
    1. Bagnall RD, Ingles J, Dinger ME, Cowley MJ, Ross SB, Minoche AE, Lal S, Turner C, Colley A, Rajagopalan S, Berman Y, Ronan A, Fatkin D, Semsarian C. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72:419-29. - PubMed
    1. Bagnall RD, Yeates L, Semsarian C. The role of large gene deletions and duplications in MYBPC3 and TNNT2 in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2010;145:150-3. - PubMed

LinkOut - more resources